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Abstract
Objective:  This  study  aims  to  assess  the  validity  of  the  ADHD  module  of  the  Mini-International
Neuropsychiatric  Interview  (MINI-Plus)  in  patients  with  substance  use  disorders  (SUD),  using  the
Conners’ Adult  ADHD  Diagnostic  Interview  for  DSM-IV  (CAADID)  as  the  external  criterion.
Method: A  cross  sectional  international  multi-center  study  in  10  countries  was  conducted  in
treatment seeking  SUD  patients.  A  sample  of  1263  patients  with  both  MINI-Plus  and  CAADID  was
analyzed  to  determine  the  psychometric  properties  of  the  MINI-Plus.
Results:  According  to  the  CAADID,  179  patients  (14.2%)  met  criteria  for  adult  ADHD,  whereas
according  to  the  MINI-Plus  227  patients  (18.0%)  were  identified  as  having  adult  ADHD.  Sensitivity
of the  MINI-Plus  ADHD  module  was  74%,  specificity  was  91%,  positive  predictive  value  was  60%
and negative  predictive  value  was  96%.  Kappa  was  0.60.
Conclusion:  The  MINI-Plus  has  acceptable  criterion  validity  for  the  screening  of  adult  ADHD  in
treatment  seeking  SUD  patients.
Scientific  significance: On  the  basis  of  the  results,  The  MINI-Plus  may  be  used  for  the  screening
of ADHD  in  SUD  patients.
©  2020  The  Author(s).  Published  by  Elsevier  Espan˜a,  S.L.U.  on  behalf  of  SEP  y  SEPB.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Validez  del  módulo  TDAH  de  Mini-International  Neuropsychiatric  Interview  PLUS  para
cribar  TDAH  en  adultos  en  pacientes  con  trastornos  por  abuso  de  sustancias  que
buscan  tratamiento
Resumen
Objetivo:  El  objetivo  de  este  estudio  es  evaluar  la  validez  del  módulo  TDAH  de  MINI-Plus  (Mini-
International  Neuropsychiatric  Interview)  en  pacientes  con  trastornos  por  abuso  de  sustancias
(SUD), utilizando  CAADID  (Entrevista  diagnóstica  Conners  para  adultos  con  TDAH  para  DSM-IV)
como criterio  externo.
Método:  Este  estudio  internacional  transversal  multicéntrico  realizado  en  10  países  fue  real-
izado en  los  pacientes  de  SUD  que  buscan  tratamiento.  Se  analizó  una  muestra  de  1.263
pacientes  utilizando  MINI-Plus  y  CAADID,  para  determinar  las  propiedades  psicométricas  de
MINI-Plus.
Resultados:  Conforme  a  la  CAADID,  179  pacientes  (14,2%)  cumplieron  los  criterios  de  TDAH  en
adultos, mientras  que,  conforme  a  MINI-Plus  se  identificaron  227  pacientes  (18%)  con  TDAH  en
adultos. La  sensibilidad  del  módulo  TDAH  de  MINI-Plus  fue  del  74%,  la  especificidad  del  91%,  el
valor predictivo  positivo  del  60%  y  el  valor  predictivo  negativo  del  96%.  El  valor  kappa  fue  de
0,60.
Conclusión:  La  MINI-Plus  tiene  validez  de  criterios  aceptable  para  el  cribado  de  TDAH  en  adul-
tos, en  pacientes  con  SUD  que  buscan  tratamiento.
Significación  científica:  Sobre  la  base  de  estos  resultados,  puede  utilizarse  MINI-Plus  para  el
cribado de  TDAH  en  los  pacientes  con  SUD.
© 2020  El  Autor(s).  Publicado  por  Elsevier  Espan˜a,  S.L.U.  en  nombre  de  SEP  y  SEPB.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).lidity  of  the  ADHD  module  of  the  Mini  International  Neu-
reatment  seeking  substance  use  disorder  patients:  ADHD
0.  https://doi.org/10.1016/j.rpsm.2020.04.013
 IN+Model
e
u
t
u
A
s
M
W
s
s
f
g
S
s
a
c
F
t
s
s
t
I
m
F
a
e
p
P
T
s
c
t
c
i
s
c
e
c
P
I
o
s
s
S
p
m
C
a
aARTICLERPSM-487; No. of Pages 7
ADHD  screening  with  MINI-Plus  
Introduction
Attention-deficit/hyperactivity  disorder  (ADHD)  is  a
childhood  onset  disorder  that  frequently  persists
into  adulthood  characterized  by  inattention  and/or
hyperactivity--impulsivity.1--3 In  the  general  population,  the
prevalence  of  ADHD  in  adults  ranges  between  2  and  5%.1,2
ADHD  has  been  associated  with  many  psychiatric  comorbidi-
ties,  including  mood  disorders,  anxiety  and  substance  use
disorders  (SUD).1--4 More  than  30%  of  patients  with  ADHD  also
develop  lifetime  SUD,5 and  ADHD  is  considered  a  risk  factor
for  the  development  of  SUD.6 On  the  other  hand,  about
20--25%  of  adult  SUD  patients  fulfill  criteria  for  ADHD.4
It  should  be  noted,  that  the  prevalence  of  ADHD  in  SUD
patients  varies  due  to  differences  between  classification
systems  (DSM-IV  vs.  DSM-5),  diagnostic  instruments,  primary
substance  used  (alcohol  vs.  drugs),  and  treatment  setting
(inpatients  vs.  outpatients).7 In  a  meta-regression  analysis,
a  substantial  part  of  the  between  study  heterogeneity
of  ADHD  prevalence  in  SUD  patients  was  explained  by
differences  in  the  diagnostic  instruments  that  were  used.8
Diagnosing  ADHD  in  SUD  patients  is  a  challenge  given
the  overlap  of  symptoms,9 and  very  few  diagnostic  and
screening  instruments  for  ADHD  have  been  validated  in  SUD
patients.  This  poses  obstacles  for  diagnosis  and  treatment
of  these  patients.10 This  is  a  clinically  urgent  issue  because
the  correct  diagnosis  of  ADHD  in  SUD  patients  provides  a
target  for  treatment.  Currently  many  patients  remain  undi-
agnosed  and  untreated,  which  has  serious  implications  on
their  prognosis.11 In  past  years,  research  efforts  have  been
made  to  evaluate  screening  and  diagnostic  instruments  for
the  assessment  of  adult  ADHD  in  SUD  patients.11--15 Despite
these  efforts,  many  questions  remain  and  more  research  is
needed.
The  Mini-International  Neuropsychiatric  Interview  (MINI-
Plus)  is  a  fully  structured  interview  that  provides  a  brief  and
accurate  assessment  of  former  Axis  1  and  some  Axis  2  psy-
chiatric  disorders  in  DSM-IV  and  ICD-10.16,17 The  MINI-Plus
provides  an  accurate  diagnosis  in  some  disorders,  using  a
short-structured  interview  which  is  well  received  by  patients
and  professionals.3,17,18 Furthermore,  this  interview  can  be
performed  by  lay  persons  after  a  brief  training.19 Com-
parisons  between  the  MINI-Plus  and  the  Structured  Clinical
Interview  for  DSM-IV-TR  axis  I  disorders  (SCID-I)20 have
yielded  kappa  values  of  0.70  or  above  for  most  diagnoses.21
In  a  clinical  study,  the  MINI-Plus  diagnosed  comorbidities,
including  substance  dependence,  better  than  a  clinical
interview.18 The  MINI-Plus  has  a  specific  DSM-IV  ADHD  mod-
ule  (for  children  and  adults),  but  this  interview  does  not
distinguish  between  presentations  of  ADHD  (inattentive,
hyperactive/impulsive,  combined).  It  is  interesting  to  point
out  that,  although  the  MINI-Plus  items  for  ADHD  are  not  iden-
tical  to  DSM-5  criteria,  the  MINI-Plus  may  be  used  for  ADHD
detection  in  adults  (with  5  criteria  as  DSM-5  requires)  as
this  instrument  covers  the  current  core  ADHD  symptoms.3
The  ADHD  module  of  the  MINI-Plus  has  never  been  evalu-
ated  in  patients  with  a  comorbid  SUD  diagnosis  and  no  data
are  available  about  its  psychometric  features.Please  cite  this  article  in  press  as:  Palma-Álvarez  RF,  et  al.  Va
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Therefore,  the  present  study  aimed  to  evaluate  the  cri-
terion  validity  of  the  ADHD  module  of  the  MINI-Plus  among
treatment-seeking  SUD  patients,  using  the  Conners’  Adult
ADHD  Diagnostic  Interview  for  DSM-IV  (CAADID)22 as  the
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xternal  criterion.  The  CAADID  is  one  of  the  most  frequently
sed  semi-structured  diagnostic  interviews  for  the  classifica-
ion  of  the  DSM-IV-TR  diagnosis  adult  ADHD.22 It  is  clinically
seful,23 and  has  shown  good  concurrent  validity  with  the
DHD  module  of  the  Psychiatric  Research  Interview  for  Sub-
tance  and  Mental  Disorders  (PRISM).24
ethods
e  analyzed  data  from  the  International  ADHD  in  Sub-
tance  Use  Disorders  Prevalence  (IASP)  study;25 a  cross
ectional  study  comprising  47  addiction  treatment  centers
rom  10  countries  across  three  continents:  Australia,  Bel-
ium,  France,  Hungary,  The  Netherlands,  Norway,  Spain,
weden,  Switzerland  and  The  United  States.25 The  IASP
tudy  used  a  two-staged  study  design,  including  a screening
nd  a  diagnostic  stage  directed  at  ADHD  and  comorbid  psy-
hiatric  disorders  in  treatment-seeking  SUD  patients,7,25 see
ig.  1. The  time  between  first  and  second  stages  was  14  days;
he  duration  of  the  first  stage  was  one  hour,  while  the  second
tage  required  at  least  three  consecutive  visits  (one-hour
ession),  depending  on  the  patient,  in  order  to  complete  all
he  assessment.25 The  current  validation  study  only  includes
ASP  participants  who  completed  both  the  MINI-Plus  ADHD
odule  and  the  CAADID.  Therefore,  only  participants  from
rance,  Hungary,  Norway,  The  Netherlands,  Spain,  Sweden
nd  Switzerland  were  included.25 Approval  was  granted  at
ach  center  by  the  local  medical  ethical  committee.  All
articipants  gave  written  informed  consent.
articipants
he  IASP  study  included  adults  (age  18--65  years),  who  were
tarting  a  new  treatment  episode  in  an  addiction  treatment
enter  between  July  2008  and  November  2011  (each  cen-
er  recruited  patients  for  one  year).  The  following  exclusion
riteria  were  applied:  inadequate  language  skills,  cognitive
mpairment,  substance  intoxication,  acute  psychiatric  crisis,
evere  somatic  problems  and  unwillingness  to  sign  informed
onsent.  Efforts  were  made  to  include  subjects  that  were
xcluded  initially  (due  to  substance  intoxication,  acute  psy-
hiatric  or  medical  problems)  at  a  later  date.25
rocedure
n  the  two-stage  design,  patients  that  participated  in  stage
ne  were  invited  to  continue  to  stage  two.  Stage  one  was  a
creening  phase  that  assessed  sociodemographic  variables,
ubstance  use  and  screened  for  ADHD  using  the  Adult  ADHD
elf-Report  Scale  V1.1  (ASRS).26 Stage  two  was  a  diagnostic
hase  consisting  of  the  CAADID  and  the  MINI-Plus  ADHD  adult
odule  (5.0  version)  for  the  diagnosis  of  (adult)  ADHD.  The
AADID  was  used  as  the  Gold  Standard.  Trained  clinicians
dministered  the  interviews,  the  CAADID  and  MINI-Plus  were
dministered  by  the  same  parson.lidity  of  the  ADHD  module  of  the  Mini  International  Neu-
reatment  seeking  substance  use  disorder  patients:  ADHD
0.  https://doi.org/10.1016/j.rpsm.2020.04.013
tatistical  analysis
riterion  validity  of  the  MINI-Plus  ADHD  module  was  assessed
y  calculating  the  sensitivity,  specificity,  positive  predictive
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All patients referred to participating site
Selection: ran dom sa mple, representing  popu lation of
site.  Procedu res for randomization diff ered by site and
were related to patient flow and availability of research
staff.       
Stage 1: Screening
Demographics
ADHD -  screener: ASRS  V 1.1
Substance  use que stion naire 
Selection : all subjects from stage 1 were asked t o
participa te in stage  2. 
Stag e 2: Full  asse ssment –  include d group 
2nd screening ADHD: ASRS V 1.1
SUD  diagnos is:  MINI- Plus modules
ADHD diagnos is: CAA DID/Mini- Plus mod ules
Stag e 2: Full  assessment –  drop  out
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nFigure  1  
alue  (PPV)  and  negative  predictive  value  (NPV)  for  the  MINI-
lus  diagnosis  as  a  predictor  of  the  CAADID  diagnosis.  We
alculated  a  95%  confidence  interval  for  each  validity  esti-
ate.  The  Kappa  index  was  calculated  as  a  global  measure
f  chance-corrected  agreement.  Statistical  analyses  were
erformed  using  SPSS  version  20.0.
esults
f  the  original  IASP  sample  (N  =  3558  subjects),27 data  on
oth  MINI-Plus  ADHD  module  and  CAADID  was  available  for
263  subjects  (final  sample  for  the  present  study).  Table  1
hows  the  sociodemographic  characteristics:  mean  age  40.0
ears  (age  range  =  18--65),  male  (73.5%),  Caucasian  (90.3%),
ingle  (54.2%),  unemployed  (38.5%),  living  alone  (41.8%).
he  main  substances  used  were  alcohol  (54.2%),  stimulants
15.0%),  cannabis  (10.8%),  and  opioids  (10.8%).
According  to  the  CAADID,  179  patients  (14.2%)  met
riteria  for  adult  ADHD,  whereas  according  to  the  MINI-
lus  227  patients  (18.0%)  were  identified  as  having  adult
DHD.  The  sensitivity  of  the  MINI-Plus  ADHD  module  as  a
redictor  of  the  CAADID  was  74.8%  (95%CI  =  [0.68--0.80]).
he  specificity  was  91.4%  (95%CI  =  [0.90--0.93]).  The  PPV
as  60.0%  (95%CI  =  [0.52--0.65])  and  the  NPV  was  95.6%
95%CI  =  [0.95--0.97]).  Finally,  the  chance-corrected  agree-
ent  between  the  MINI-Plus  ADHD  module  and  the  CAADID
howed  a  Kappa  index  of  0.60  (95%CI  =  [0.53--0.66]).
iscussion
n  the  current  study  among  treatment  seeking  SUD  patients,
he  MINI-Plus  overestimates  the  prevalence  of  adult  ADHD
ompared  to  the  CAADID:  18.0%  vs.  14.2%.  These  results  arePlease  cite  this  article  in  press  as:  Palma-Álvarez  RF,  et  al.  Va
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imilar  to  those  reported  by  researches  that  have  used  MINI-
lus  for  studying  ADHD  in  general  population  (13.8%).3 Our
esults  could  also  be  related  to  the  good  specificity  (91%)  and
oderate  sensitivity  (74%)  of  the  MINI-Plus.  With  its  high  NPV
A
a
t
dn  of  study.
96%)  and  moderate  PPV  (60%),  the  MINI-Plus  is  well-suited
o  detect  adult  ADHD  patients,  but  patients  positive  for  adult
DHD  should  be  clinically  assessed  to  prevent  false  posi-
ive  cases  of  adult  ADHD  in  treatment-seeking  SUD  patents.
PV  and  PPV  values  may  change  in  samples  with  a  different
revalence  of  ADHD  prevalence.28 These  results  suggest  that
he  MINI-Plus  might  be  more  suitable  as  a  screener  than  as
 diagnostic  tool  for  ADHD  in  SUD  patients.
Our  results  with  the  MINI-Plus  are  better  than  those  with
ther  screening  instruments  for  ADHD  in  SUD  patients.  Van
e  Glind  et  al.  (2013)  studied  the  ASRS  as  a  screening  instru-
ent  for  ADHD  in  a  SUD  population  with  the  CAADID  as  the
xternal  criterion.27 The  ASRS  had  a  similar  NPV  (97%)  but  a
uch  lower  PPV  (26%)  in  a  similar  population  with  the  same
revalence.27 The  ASRS  had  a  higher  sensitivity  (84%)  but  a
uch  lower  specificity  (66%)  compared  with  the  MINI-Plus.
herefore,  the  MINI-Plus  could  be  cautiously  considered  as
 better  instrument  than  the  ASRS  for  ADHD  screening  in
reatment  seeking  SUD  patients.  This  is  because,  a  screen-
ng  test  should  have  a  high  sensitivity  and  good  specificity,
ut  however,  NPV  and  PPV  are  key  characteristics  due  to  the
act  that  they  describe  the  performance  of  a  test  in  a  spe-
ific  population  with  a  specific,  i.e.  substantial,  prevalence
f  ADHD.29
According  to  the  Kappa  index  (0,60),  the  agreement
etween  the  CAADID  and  MINI-Plus  diagnoses  was  moderate.
revious  studies  on  the  diagnostic  agreement  between  MINI-
lus  and  other  diagnostic  instruments  (e.g.,  SCID-I)  have
hown  a  higher  Kappa  index  for  most  diagnoses,  including
dult  ADHD.16,21 One  study  found  major  diagnostic  disagree-
ent  in  33%  of  cases  when  the  MINI-Plus  was  used,  but  it  was
ompared  with  an  unstructured  interview18 and  the  study  did
ot  specify  whether  ADHD  was  actively  searched  for.
Some  studies  have  used  the  MINI-Plus  to  diagnose  adultlidity  of  the  ADHD  module  of  the  Mini  International  Neu-
reatment  seeking  substance  use  disorder  patients:  ADHD
0.  https://doi.org/10.1016/j.rpsm.2020.04.013
DHD  in  other  populations  not  selected  for  SUD,  such
s  incarcerated  participants,30 adult  psychiatric  outpa-
ients  without  psychotic  disorders,31 patients  with  mood
isorders,32 psychiatric  inpatients,33 and  patients  in  an
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Table  1  Sociodemographic  and  clinical  characteristics.
Variables  n  =  1263
Age  (years)  M  =  39.98  (18--65)
Gender  73.5%  (928)  males
Social  status %  (n)
Single  54.2  (685)
Divorced  18.8  (237)
Married  17.1  (216)
Living partner  8.7  (110)
Unknown-missing  1.2  (15)
Laboral  status  %  (n)
Unemployed  38.5  (486)
Employed  30.1  (210)
Sick leave  16.6  (210)
Disability  12.2  (154)
Unknown-missing  2.6  (33)
Housing  %  (n)
Alone  41.8%  (528)
With  partner  26.1%  (330)
With  parents 15.8%  (199)
With  friends  4.6%  (58)
Homeless  4.2%  (53)
Shelter/health  care  4.1%  (52)
Unknown-missing  3.4%  (43)
Ethnicity  %  (n)
Caucasian  90.3%  (1141)
Other  9.7%  (122)
Main substance  %  (n)
Alcohol  54.2%  (684)
Stimulants  15.0%  (190)
Cannabis  10.8%  (137)
Opioids  10.8%  (136)
Prescription  medication  4.6%  (58)
Other 4.0%  (51)
Unknown-missing  0.6%  (7)
ADHD diagnosis  according  to  CAADID %  (n)
No ADHD  patients  85.8%  (1084)
ADHD  14.2%  (179)
ADHD  diagnosis  according  to  MINI-Plus  %  (n)
No ADHD  patients  82.0%  (1036)
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years:  Eli-Lilly,  Shire,  Janssen,  Rovi,  Lundbeck,  and  Rubió.ADHD  18.0%  (227)
acute  psychiatric  ward.34 Although  DSM-5  criteria  for  ADHD
are  not  the  same  to  the  MINI-Plus  items,  the  latter  instru-
ment  could  be  used  for  ADHD  detection  in  adults  (with
5  criteria  as  DSM-5  requires)  because  this  interview  cov-
ers  the  current  core  ADHD  symptoms.3 Moreover,  some
researches  have  used,  analyzed  and  adapted  the  MINI-Plus  to
fit  to  DSM-5  five  criteria  with  good  results.3 To  the  best  of  our
knowledge,  there  are  no  studies  in  SUD  patients  that  eval-
uated  the  MINI-Plus  properties  for  ADHD.  Therefore,  this  is
the  first  study  of  the  validity  of  the  ADHD  module  of  MINI-PlusPlease  cite  this  article  in  press  as:  Palma-Álvarez  RF,  et  al.  Va
ropsychiatric  Interview  PLUS  for  screening  of  adult  ADHD  in  t
screening  with  MINI-Plus.  Rev  Psiquiatr  Salud  Ment  (Barc.).  202
in  SUD  patients.
Adult  ADHD  in  SUD  patients  has  also  been  assessed  with
the  PRISM,35 a  diagnostic  instrument  that  was  specifically
developed  for  this  population.  In  a  preliminary  study,  the
d
a PRESS
5
DHD  section  of  the  PRISM  showed  high  sensitivity  and  speci-
city  in  SUD  patients  with  clinical  diagnosis  as  external
riterion.24 It  should  be  noted,  however,  that  the  PRISM
equires  at  least  two  days  training  and  that  administration
akes  about  two  hours.36 In  contrast,  the  MINI-Plus  needs  less
raining  and  much  less  time  to  administer.19,21,30 A  specific
imitation  of  the  ADHD  module  of  MINI-Plus  is  that  it  does
ot  differentiate  between  ADHD  presentations/subtypes.
The  present  study  has  both  strengths  and  limitations.  The
ain  strengths  are  the  large  and  diverse  sample  of  treat-
ent  seeking  SUD  patients  (that  represents  daily  clinical
ractice  in  outpatient  treatment  centers)  and  the  use  of
nternationally  available  instruments  within  the  same  study
rotocol  in  different  countries  and  treatment  settings.  An
mportant  limitation  is  the  lack  of  clinical  information  to
heck  the  value  of  the  CAADID  as  external  criterion  (‘‘gold
tandard’’).  Besides,  some  authors  describe  that  lowering
he  CAADID  cut-off  may  increase  ADHD  diagnosis,  and  there-
ore,  it  modifies  any  comparison  with  other  instruments37;
owever,  in  the  current  work,  we  used  the  validated,  more
onservative  and  recommended  cut-off.  Another  important
imitation  is  the  lack  of  data  on  current  drug  use  and  the
ossible  influence  of  ongoing  drug  use  on  the  stability  and
alidity  of  an  ADHD  diagnosis  in  SUD  patients.  However,
 recent  analysis  of  the  ADHD  screening  data  within  the
urrent  study  suggests  that  this  is  not  a  real  problem.15
inally,  the  administration  of  the  CAADID  and  MINI-Plus  by
he  same  person  could  generate  a  confirmation  bias  due  the
valuator  could  interpret  or  assess  according  to  previous
nformation.38
In  conclusion,  the  MINI-Plus  has  acceptable  psychome-
ric  features  for  the  screening  of  adult  ADHD  in  treatment
eeking  SUD  patients.  In  order  to  prevent  false  positive  diag-
oses,  a  structured  clinical  assessment  should  be  performed
n  all  patients  with  adult  ADHD  according  to  the  MINI-Plus.
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